Business Standard

Tuesday, January 21, 2025 | 05:44 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Pharmaceutical Companies

Dr Reddy's Labs Q3 Preview: Revlimid to dent US sales, profits may rise 12%

Indian pharmaceutical (IT) major, Dr Reddy's Laboratories, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Thursday, January 23, 2025

Dr Reddy's Labs Q3 Preview: Revlimid to dent US sales, profits may rise 12%
Updated On : 20 Jan 2025 | 4:23 PM IST

Takeda opens Bengaluru ICC, targets 750 employees to boost India presence

The flagship ICC in Bengaluru complements Takeda's existing centres in Slovakia and Mexico, highlighting its strategic focus on data and advanced digital technologies

Takeda opens Bengaluru ICC, targets 750 employees to boost India presence
Updated On : 15 Jan 2025 | 6:25 PM IST

Senores gains 43% on stock market debut; Ventive up 10%, Carraro dips 10%

The listing day performance was largely in line with the subscription levels for the threen IPOs

Senores gains 43% on stock market debut; Ventive up 10%, Carraro dips 10%
Updated On : 31 Dec 2024 | 1:16 AM IST

Lupin acquires Huminsulin from Lilly to strengthen diabetes portfolio

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and children

Lupin acquires Huminsulin from Lilly to strengthen diabetes portfolio
Updated On : 30 Dec 2024 | 9:57 PM IST

Healthcare sector in India to reach $320 billion by 2028, says report

India's pharmaceutical sector is targeting $130 billion by 2030 and biotechnology is aiming for $300 billion by the same year: Great Place To Work report

Healthcare sector in India to reach $320 billion by 2028, says report
Updated On : 26 Dec 2024 | 4:46 PM IST

CRISIL analysis: Exports, domestic demand to drive pharma sector's growth

Bulk drug exports are expected to see moderate increases, supported by volume growth from new launches, customised synthesis, and rising demand for complex drugs

CRISIL analysis: Exports, domestic demand to drive pharma sector's growth
Updated On : 24 Dec 2024 | 6:59 PM IST

Despite short-term blip, Sun Pharma remains favourite among investors

According to Bloomberg, 30 of 41 analysts are bullish on Sun Pharma, while the remaining seven have a neutral rating and only 4 are bearish

Despite short-term blip, Sun Pharma remains favourite among investors
Updated On : 20 Dec 2024 | 11:56 PM IST

NGT issues notice to environment ministry over Hyderabad pharma unit blast

The National Green Tribunal has sought a response from the Hyderabad regional office of the Union Ministry of Environment Forest and Climate Change and others on the blast at a pharmaceutical company in Hyderabad last month that left one dead and three others injured. The green body was hearing a matter where it had taken suo motu (on its own) cognisance of a PTI report published on November 21 titled 'One dead, three injured in reactor blast at pharma company in Hyderabad.' In an order dated November 28, a bench of NGT Chairperson Justice Prakash Shrivastava said, "The news item relates to a flash fire triggered by a reactor blast at a pharmaceutical company in Hyderabad, resulting in the death of one man and injuries caused to three others. As per the article, the incident occurred while the four workers were repairing the reactor." The bench also comprising judicial member Justice Arun Kumar Tyagi and expert member A Senthil Vel said the news item did not indicate whether steps h

NGT issues notice to environment ministry over Hyderabad pharma unit blast
Updated On : 08 Dec 2024 | 2:57 PM IST

Sun Pharma Q1 results: Profit zooms 40% on robust global specialty sales

On a sequential basis, the company exhibited a 6.8 per cent rise in net profit, while its revenue grew by 5.5 per cent, from Rs 2,655 crore and Rs 12,380.7 crore reported in Q3 FY24, respectively

Sun Pharma Q1 results: Profit zooms 40% on robust global specialty sales
Updated On : 01 Aug 2024 | 11:31 PM IST

Cipla Q1 Preview: Restructure in biz may dent sales; profits to rise 7%

Cipla is expected to see a decent June quarter with revenues estimated to increase in upper single digits on a year on year basis and net profits seeing a mid single digit growth

Cipla Q1 Preview: Restructure in biz may dent sales; profits to rise 7%
Updated On : 24 Jul 2024 | 10:44 AM IST

Indian pharma firms seek govt tax reliefs, incentives to spur innovation

The upcoming budget would be Modi's first major policy announcement in his third term as prime minister

Indian pharma firms seek govt tax reliefs, incentives to spur innovation
Updated On : 07 Jul 2024 | 7:18 PM IST

Emcure Pharma seeks to raise Rs 1,952 cr through IPO, issue opens July 3

Fourth largest IPO of 2024; company will use the proceeds to repay debt and for general corporate purposes

Emcure Pharma seeks to raise Rs 1,952 cr through IPO, issue opens July 3
Updated On : 28 Jun 2024 | 11:05 PM IST

Emcure Pharma, HDT settle legal fight over Covid vaccine technology

The companies said they have signed a long-term agreement to continue collaborating on the development of mRNA-based vaccines and a license that allows Emcure to use HDT's mRNA technology

Emcure Pharma, HDT settle legal fight over Covid vaccine technology
Updated On : 24 May 2024 | 10:27 PM IST

Emcure, Gennova settle legal dispute with US-based HDT Bio, sign agreement

Litigation before courts in the US and arbitral tribunal in London settled, two sides say

Emcure, Gennova settle legal dispute with US-based HDT Bio, sign agreement
Updated On : 23 May 2024 | 3:12 PM IST

Zydus, MSN partner to license, supply affordable cancer tablets in the US

MSN Lab will manufacture and supply Cabozantinib; Zydus will handle marketing, distribution and sales

Zydus, MSN partner to license, supply affordable cancer tablets in the US
Updated On : 17 May 2024 | 3:29 PM IST

India raises issue of pharma pricing control in Australia on generic drugs

India has raised the issue of pharmaceutical pricing control in Australia, particularly on generic medicines, during a recent bilateral meeting between the officials of the two countries. The two sides have decided to work closely on timely resolution of market access issues, deepen people-to-people contacts, and create an institutional mechanism for sharing of preferential import data, the commerce ministry said on Saturday. The bilateral trade between the countries declined 7.7 per cent to USD 24 billion in 2023-24 as against USD 26 billion in 2022-23. These issues among others were discussed during the first Joint Committee Meeting (JCM) in Canberra under India-Australia Economic Co-operation and Trade Agreement (Ind-Aus ECTA). "Both the sides while acknowledging the smooth implementation of the ECTA, briefly elaborated on ECTA implementation issues including MRAs (mutual recognition agreements) on organic products, market access issues related to products like okra, pomegranate

India raises issue of pharma pricing control in Australia on generic drugs
Updated On : 04 May 2024 | 9:27 PM IST

Lowering prices to weigh down earnings of Indian API players in near term

According to the brokerage, prices of APIs such as Paracetamol, Azithromycin, Montelukast, and Meropenem, have all declined in the range of 10-30 per cent over the last one year

Lowering prices to weigh down earnings of Indian API players in near term
Updated On : 02 May 2024 | 12:26 PM IST

Astrazeneca row: Only 7 in a million at risk of TTS, says ex-ICMR scientist

Former ICMR scientist Raman Gangakhedkar said the risk is highest after the initial dose, eventually decreasing with subsequent doses

Astrazeneca row: Only 7 in a million at risk of TTS, says ex-ICMR scientist
Updated On : 01 May 2024 | 8:11 PM IST

AstraZeneca vaccine: From its origin to side effects, all you need to know

Manufactured first in 2021, the AstraZeneca vaccine, known in India as Covishield, has been facing scrutiny over the years, with many countries banning it back in 2021 itself

AstraZeneca vaccine: From its origin to side effects, all you need to know
Updated On : 30 Apr 2024 | 10:48 PM IST

India becoming attractive for clinical trials, says pharma industry leaders

Over the past 10 years, clinical trials in India have become easier, more accessible and accelerated, experts from the pharma sector have said as top multinationals are increasingly looking at the country as their base for clinical trials. Data from 2017 to 2023 shows that phase two and phase three clinical trials are growing at about 15 per cent to 18 per cent in India. This is primarily because of the 10 modifications done to the Drugs and Cosmetics Act of 1940, according to Badhri Srinivasan, head of Global Clinical Operations, Novartis. Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022. Given where we are, given what the landscape in the international community has happened, the regulators in India are starting to move and make changes to it. Since 2013, there have been 10 modifications to that act to try to make clinical trials easier, more accelerated, more accessible, et cetera, Srinivasan said at the 18th Annua

India becoming attractive for clinical trials, says pharma industry leaders
Updated On : 27 Apr 2024 | 7:55 PM IST
Donโ€™t miss the latest developments in business and finance.
Later
Allow Notifications